ACTRN12613000061730Completed未知
A prospective feasibility study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer
Peter MacCallum Cancer Centre0 sites60 target enrollmentStarted: January 16, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- All
Inclusion Criteria
- •Age greater than or equal to 18 years.
- •Written informed consent has been provided.
- •FDG-PET scan performed for cancer staging.
- •Patients receiving curative intent radiotherapy for non-small cell lung cancer.
- •Minimum dose of radiotherapy prescribed is 60Gy with or without chemotherapy
- •ECOG performance status 0-2 inclusive
Exclusion Criteria
- •Participant is not able to tolerate supine position on PET/CT bed for the duration of the PET/CT acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from Intensive Care Unit).
- •Breast-feeding
Investigators
Similar Trials
Active, not recruiting
Phase 1
Pilot study for the evaluation of [68Ga]Ga-PentixaFor PET imaging for the identification of unilateral adrenal secretion of ALdosterON in patients with primary aldosteronism.Primary aldosteronism, Primary aldosteronismMedDRA version: 20.1Level: PTClassification code: 10036692Term: Primary hyperaldosteronism Class: 100000004860CTIS2023-505507-22-00Assistance Publique Hopitaux De Paris60
Active, not recruiting
Not Applicable
Development of an innovative tracer imaging of neuro-endocrine tumors and preliminary clinical evaluatioEUCTR2013-003927-12-FRCHU de Bordeaux
Recruiting
Not Applicable
A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients with Chronic Bronchitis in AustraliaEmphysemaBronchitisACTRN12617000330347Gala Therapeutics Inc.24
Active, not recruiting
Not Applicable
A phase II Feasibility Study on the use of 18Fluoro-L-Thymidine and Positron Emission Tomography (FLT-PET) on Prognosis and Staging in Patients with Locoregionally Advanced Mucosal Head and Neck Squamous Cell CarcinomaHead and Neck CancerCancer - Head and neckACTRN12613000205730Royal Brisbane and Women's Hospital10
Completed
Not Applicable
Pilot Study – Use of [68Ga] gallium-labelled Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) for the Characterisation of Metastatic Lesions in Patients with Renal Cell CarcinomaACTRN12615000854538Dr Simon Wood10